REFERENCES
- Gabizon A.A., Muggia F.M. Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors. Long Circulating Liposomes: Old Drugs, New Therapeutics, M.C. Woodle, G. Storm. Springer-Verlag and Landes Bioscience. 1998; 155–174
- Gabizon A.A. Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy. Cancer Invest. 2001; 19: 424–436
- Muggia F.M. Liposomal Encapsulated Anthracyclines: New Therapeutic Horizons. Curr. Oncol. Rep. 2001; 3: 156–162
- Lyass O., Hubert A., Gabizon A.A. Phase I Study of Doxil-Cisplatin Combination Chemotherapy in Patients with Advanced Malignancies. Clin. Cancer Res. 2001; 7: 3040–3046
- Gabizon A., Isacson R., Libson E., Kaufman B., Uziely B., Catane R., Ben-Dor C.G., Rabello E., Cass Y., Peretz T.al, e. Clinical Studies of Liposome-Encapsulated Doxorubicin. Acta Oncol. 1994; 33: 779–786
- de Marie S. Liposomal and Lipid-Based Formulations of Amphotericin B. Leukemia 10, Suppl. 1996; 2: S93–S96
- Dezube B.J. Safety Assessment: DoxilR (Doxorubicin HCl Liposome Injection) in Refractory AIDS-Related Kaposi's Sarcoma. Doxil Clinical Series. Gardiner-Caldwell SynerMed, Califon, NJ 1996; Volume 1: 1–8
- Alberts D.S., Garcia D.J. Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer. Drugs 54, Suppl. 1997; 4: 30–45
- Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F.M., Gabizon A. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During two Complementary Phase I Studies. J. Clin. Oncol. 1995; 13: 1777–1785
- Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged Circulation Time and Enhanced Accumulation in Malignant Exudates of Doxorubicin Encapsulated in Polyethylene-Glycol Coated Liposomes. Cancer Res. 1994; 54: 987–992
- Koukourakis M.I., Koukouraki S., Giatromanolaki A., Archimandritis S.C., Skarlatos J., Beroukas K., Bizakis J.G., Retalis G., Karkavitsas N., Helidonis E. Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Head and Neck Cancer. J. Clin. Oncol. 1999; 17: 3512–3521
- ALZA Pharmaceuticals Doxil Package Insert. Mountain View, CAUSA 2000
- Brouwers A.H., De Jong D.J., Dams E.T., Oyen W.J., Boerman O.C., Laverman P., Naber T.H., Storm G., Corstens F.H. Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's Disease. J. Drug Target 2000; 8: 225–233
- Szebeni J., Baranyi B., Savay S., Lutz L.U., Jelezarova E., Bunger R., Alving C.R. The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®). J. Liposome Res. 2000; 10: 347–361
- Muller-Eberhard H.J. The Membrane Attack Complex. Spring. Sem. Immunopathol. 1984; 7: 93
- Szebeni J., Fontana J.L., Wassef N.M., Mongan P.D., Morse D.S., Dobbins D.E., Stahl G.L., Bünger R., Alving C.R. Hemodynamic Changes Induced by Liposomes and Liposome-Encapsulated Hemoglobin in Pigs: A Model for Pseudo-Allergic Cardiopulmonary Reactions to Liposomes. Role of Complement and Inhibition by Soluble CR1 and Anti-C5a Antibody. Circulation 1999; 99: 2302–2309
- Szebeni J., Baranyi B., Savay S., Bodo M., Morse D.S., Basta M., Stahl G.L., Bunger R., Alving C.R. Liposome-Induced Pulmonary Hypertension: Properties and Mechanism of a Complement-Mediated Pseudoallergic Reaction. Am. J. Physiol. 2000; 279: H1319–H1328
- Szebeni J. Complement Activation-Related Pseudoallergy Caused by Liposomes, Micellar Carriers of Intravenous Drugs and Radiocontrast Agents. Crit. Rev. Ther. Drug Carr. Syst. 2001; 18: 567–606